Navigation Links
ActivBiotics Assignee Issues First Distribution of Cash to Creditors
Date:6/19/2008

WELLESLEY HILLS, Mass., June 19 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") the Assignee for the Benefit of Creditors of ActivBiotics, Inc. ("ActivBiotics") announced today the first distribution of cash to the creditors of ActivBiotics. The distribution signifies the substantial completion of the asset liquidation process and the allowance of creditors' claims. The assignment, which began the liquidation process, was a transfer of all the assets of ActivBiotics to Finn on December 7, 2007, under a common law procedure. The process was complex because ActivBiotics was a biotech start-up company with sophisticated intellectual property and fixed assets.

Finn pointed out that the assignment process allowed him to move quickly and that the distribution of cash to creditors six and a half months after the process began highlights one of the major benefits of the assignment legal process for liquidating defunct enterprises.

Finn praised the law firm he retained to assist him, Bingham McCutchen LLP, to include, but not be limited to, Edwin Smith, Meerie Joung and Jennifer Cleary.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr. is the founding partner of the firm Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-four (34) years.


'/>"/>
SOURCE ActivBiotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
2. ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer
3. ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates, on March 14, 2008
4. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
5. ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
6. Neuftec Issues Patent Infringement Proceedings in the UK Against Oxonica
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
8. Bristol-Myers Squibb Issues $1.6 Billion of Senior Notes
9. SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT
10. VaxGen Issues Rebuttal to MedCap Letter
11. pH Balanced RepHresh Vaginal Gel(R) now Available to Women in Canada Attacking Tough, Embarrassing Feminine Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the leading ... around the world, is pleased to announce the launch of a new scholarship for ... (STEM) fields. , This merit-based scholarship is open to all high school seniors, 17 ...
(Date:2/22/2017)... -- Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech Ltd.) ... Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a ... traits and nutritional products, today announced their collaboration to achieve the ... China to the United States ... ...
(Date:2/22/2017)... ROCHELLE, VIRGINIA (PRWEB) , ... February 22, 2017 ... ... announced today that Dr. Daniel Spyker, PhD, MD former Acting Deputy Director in ... in CDER’s Pilot Drug Evaluation Staff has joined the company as an Expert ...
(Date:2/22/2017)... and SAN DIEGO ... Holdings (the "Company") (OTCQB:CELZ) announced today expansion of ... donor stem cell product through establishment of laboratory ... research activities at the San Diego BioLabs facility, ... Boehringer Ingelheim, Novartis, and Sanofi. In ...
Breaking Biology Technology:
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
Breaking Biology News(10 mins):